Benigne Prostatahyperplasie: Bis zu welchem Zeitpunkt kann man konservativ behandeln?

McConnell JD et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349(25):2387–2398 Roehrborn CG (2008) BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int 101(Suppl 3):17–21 Sebastianelli A, Gacci M (2018) Current status of the relationship between metabolic syndrome and lower urinary tract symptoms. Eur Urol Focus 4(1):25–27 Berges R (2008) Epidemiology of benign prostatic syndrome. Associated risks and management data in German men over age 50. Urologe A 47(2):141–148 Chapple CR, Roehrborn CG (2006) A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 49(4):651–658 Isaacs JT (1994) Etiology of benign prostatic hyperplasia. Eur Urol 25(Suppl 1):6–9 Gratzke C et al (2015) EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 67(6):1099–1109 Bach T, Heitz M, Bruns T (2020) Benign prostatic hyperplasia : new and treatment-relevant aspects from the DGU guidelines. Urologe A 59(5):544–549 Strittmatter F et al (2013) Current pharmacological treatment options for male lower urinary tract symptoms. Expert Opin Pharmacother 14(8):1043–1054 Michel MC, Goepel M (2001) Lower urinary tract symptoms suggestive of benign prostatic obstruction—what’s the long-term effectiveness of medical therapies? Eur Urol 39(Suppl 3):20–25 Cindolo L et al (2015) Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. Eur Urol 68(3):418–425 Rosen R et al (2003) Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 44(6):637–649 D’Agate S et al (2020) Model-based meta-analysis of individual International Prostate Symptom Score trajectories in patients with benign prostatic hyperplasia with moderate or severe symptoms. Br J Clin Pharmacol 86(8):1585–1599 Izard J, Nickel JC (2011) Impact of medical therapy on transurethral resection of the prostate: two decades of change. BJU Int 108(1):89–93 Presicce F, De Nunzio C, Tubaro A (2018) Clinical implications for the early treatment of benign prostatic enlargement (BPE): a systematic review. Curr Urol Rep 19(9):70 Presicce F et al (2017) The influence of the medical treatment of LUTS on benign prostatic hyperplasia surgery: do we operate too late? Minerva Urol Nefrol 69(3):242–252 Presicce F, De Nunzio C, Tubaro A (2017) Can long-term LUTS/BPH pharmacological treatment alter the outcomes of surgical intervention? Curr Urol Rep 18(9):72 Reynard JM, Shearer RJ (1999) Failure to void after transurethral resection of the prostate and mode of presentation. Urology 53(2):336–339 Djavan B et al (1997) Urodynamic assessment of patients with acute urinary retention: is treatment failure after prostatectomy predictable? J Urol 158(5):1829–1833 Blatt AH et al (2012) Transurethral prostate resection in patients with hypocontractile detrusor – what is the preditctive value of ultrastructural detrusor changes? J Urol 188(6):2294–2299